				<section class="content container">
					<p class="boxed blue">ABILIFY<sup>&reg;</sup> (aripiprazole) is indicated for use as an adjunctive therapy to antidepressants in adults with<br>Major Depressive Disorder who have had an inadequate response to antidepressant therapy.</p>
					<h6>MDD treatment response rate dropped as the number of treatment steps increased<sup>1</sup></h6>
					<img src="http://placehold.it/784x450">
					<p class="eighty-percent"><sup>a</sup>Switch in same class or different class or augment (different class). Cognitive behavioral therapy (CBT) may also be added.<br><sup>b</sup>Switch to another class or augment with non-antidepressant.</p>
					<p class="eighty-percent">Sequenced Treatment Alternatives to Relieve Depression (STAR*D) study was a government-sponsored, multicenter, multilevel, randomized, real-world clinical study enrolling more than 4,000 adult outpatients with nonpsychotic MDD to determine the effectiveness of different treatments on those patients who have not responded to initial treatment with an antidepressant.</p>
					<p class="eighty-percent">*Response was defined as a &GreaterEqual;50% decrease in the 16-item Quick Inventory of Depressive Symptomatology-Self Report (QIDS-SR). Patients who did not achieve a satisfactory response or did not tolerate a specific treatment step were encouraged to proceed to the next treatment step.</p>
					<p class="boxed navy">Approximately 2 out of 3 patients treated for depression still had unresolved symptoms<sup>3</sup></p>
					<h6>American Psychiatric Association (APA) guidelines for acute-phase treatment of MDD<sup>4</sup></h6>
					<img src="http://placehold.it/784x600" style="margin-bottom:2em;">
					<h6 style="margin-bottom: .2em;">APA MDD Practice Guidelines included continual evaluation</h6>
					<h6 class="navy" style="margin:.2em auto 2em;"><em>&quot;Throughout treatment, both the patient&apos;s response and the adequacy<br>of treatment must be vigilantly and systematically monitored.&quot;<sup>4</sup></em></h6>
					<h5 class="eighty-percent">Indication</h5>
    				<p class="eighty-percent">ABILIFY<sup>&reg;</sup> is indicated for use as an adjunctive therapy to antidepressants in adults with Major Depressive Disorder who have had an inadequate response to antidepressant therapy.</p>
					<h5 class="eighty-percent">Contraindication</h5>
    				<p class="eighty-percent">Known hypersensitivity reaction to ABILIFY<sup>&reg;</sup>. Reactions have ranged from pruritus.urticaria to anaphylaxis.</p>
				</section>
			
				<?php include '../inc/isi.php'; ?>

				<section class="references container" id="references">
					<p><strong>References:</strong></p>
					<ol class="reference">
						<li>Rush AJ, Trivedi MH, Wisniewski SR, et al. Acute and longer-term outcomes in depressed outpatients requiring one or several treatment steps: a STAR*D report. <em>Am J Psychiatry</em>. 2006;163(11):1905-1917.</li>
						<li>Rush AJ, Fava M, Wisniewski SR, et al. Sequenced treatment alternatives to relieve depression (STAR*D): rationale and design. <em>Control Clin Trials</em>. 2004;25(1):119-142.</li>
						<li>Trivedi MH, Rush AJ, Wisniewski SR, et al. Evaluation of outcomes with citalopram for depression using measurement-based care in STAR*D: implications for clinical practice. <em>Am J Psychiatry</em>. 2006;163(1):28-40.</li>
						<li>American Psychiatric Association. Practice guideline for the treatment of patients with major depressive disorder. 3rd ed.<br><a href="http://psychiatryonline.org/pdfaccess.ashx?ResourceID=243261&PDFSource=6">http://psychiatryonline.org/pdfaccess.ashx?ResourceID=243261&PDFSource=6</a>. Published October 2010. Accessed January 22, 2013.</li>
					</ol>
				</section>